Truist has a ‘Buy’ rating on the shares with a price target of $205, representing a potential upside of about 51% from Friday’s closing price. ăƒ»Truist’s current base assumption is that Arikayce sales ...
Dear Doctors: I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called mycobacterium avium complex. Would you kindly consider discussing ...
Shares of Insmed climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections. The stock rose 10%, to $150.02, in ...
Wall Street’s hoped-for phase III derisking event from Insmed Inc. materialized, and shares of the firm (NASDAQ:INSM) closed Sept. 5 at $26.37, up $3.73, or 16.5%, on positive top-line results from ...
AN2 Therapeutics Inc (NASDAQ:ANTX) has voluntarily paused Phase 3 enrollment in the Phase 2/3 trial (EBO-301) evaluating epetraborole in treatment-refractory Mycobacterium Avium Complex (MAC) lung ...
A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease has been discontinued. The ...
DEAR DOCTORS: I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called mycobacterium avium complex. Would you kindly consider discussing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results